title: Eziopitant. Pfizer.
abstract: Pfizer is developing ezlopitant, a neurokinin-1 antagonist, for the potential treatment of irritable bowel syndrome (IBS). The compound had undergone phase II trials in the US and Europe, and phase I in Japan for treatment of chemotherapy-induced emesis [290988], [320737], [329187]. A phase II, double-blind, randomized study was performed to assess the safety and efficacy of ezlopitant for the control of cisplatin-induced emesis. Treatment was well tolerated [290988]. Although the compound effectively controls emesis, it is less effective in controlling nausea, and development has been discontinued for the emesis indication [347367]. Ezlopitant has undergone a pilot study in 14 IBS patients [367631].
authors.affiliation: Menarini Ricerche SpA, Sette Santi, Florence, Italy. sevangelista@menarini-ricerche.it
authors.forename: S
authors.initials: S
authors.lastname: Evangelista
mesh_terms: D000818:Animals; D001596:Benzylamines / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D064729:Neurokinin-1 Receptor Antagonists; D013329:Structure-Activity Relationship
chemical_list: D001596:Benzylamines; D019086:Bridged Bicyclo Compounds, Heterocyclic; D005765:Gastrointestinal Agents; D064729:Neurokinin-1 Receptor Antagonists; C413864:ezlopitant